Teenage girls with ADHD may struggle scholastically and socially. But because symptoms of inattention are more likely to be predominant than symptoms of hyperactivity/impulsivity in girls with the disorder, ADHD may not be suspected. Diagnosis and intervention may be critical to continued success.

Hayden*—a 17-year-old starting her senior year in high school

**HISTORY:**

- Hayden has been anxious about the growing pressure to perform well in school in order to get into college.
- Although not previously diagnosed with ADHD, she’s been experiencing ADHD-like symptoms for the past 2 years but has been able to cope thus far.
- She currently finds it more and more challenging to focus in school, as well as in the new part-time job she took to help save for college.
- She and her parents are concerned about her struggle to stay focused at such a critical time in her life, and decided to seek an evaluation and possible therapy.

*Patient portrayal.

**EVEKEO® can be an integral part of a total treatment program for patients with ADHD**

The *only* single-salt, immediate-release 1:1 racemic mixture of dextroamphetamine and levoamphetamine.

**INDICATION**

Evekeo® (amphetamine sulfate tablets, USP) is a prescription medicine for the treatment of narcolepsy, attention deficit disorder with hyperactivity as an integral part of a total treatment program and exogenous obesity as a short term adjunct in a regimen of weight reduction.

**IMPORTANT SAFETY INFORMATION**

Evekeo (amphetamine sulfate tablets, USP) is a federally controlled substance (CII) with a high risk of abuse or dependence. Prolonged use may lead to drug dependence and must be avoided. Subjects may obtain Evekeo for illegal non-therapeutic use or distribution to others, and therefore it should be prescribed or dispensed sparingly.

Misuse of Evekeo may cause sudden death and serious cardiovascular adverse events.

Please see full Important Safety Information on reverse and full Prescribing Information and Medication Guide, including Boxed Warning regarding abuse and dependence, in the pocket.
**Indication**

Evekeo® (amphetamine sulfate tablets, USP) is a prescription medicine for the treatment of narcolepsy, attention deficit disorder with hyperactivity as an integral part of a total treatment program and exogenous obesity as a short term adjunct in a regimen of weight reduction.

**Important Safety Information**

**Contraindications**

Evekeo is contraindicated in patients:

- with a history of advanced arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension, hyperthyroidism, known hypersensitivity or idiosyncrasy to the sympathomimetic amines
- that are tense or agitated
- with a history of drug abuse
- taking or who have taken monoamine oxidase inhibitor (MAOI) within 14 days. Hypertensive crises may result.

**Warnings and Precautions**

Sudden death has been reported in children and adolescents with structural cardiac abnormalities or other serious heart problems in association with CNS stimulant treatment at usual doses. Sudden death, stroke and myocardial infarction have been reported in adults taking stimulant drugs at usual doses for ADHD. Stimulant medications can cause an increase in blood pressure (mean increase about 2-4 mmHg) and heart rate (mean increase about 3-6 bpm). All patients should be monitored for larger changes in heart rate and blood pressure.

Children, adolescents, or adults who are being considered for treatment with Evekeo should have a careful history (including assessment for a family history of sudden death or ventricular arrhythmia) and physical exam to assess for the presence of cardiac disease. **Patients developing any signs of heart problems such as exertional chest pain, unexplained syncope, or other symptoms suggestive of cardiac disease while taking Evekeo should undergo a prompt cardiac evaluation.**

Stimulants may exacerbate symptoms in patients with pre-existing psychotic disorder or in patients with new or worsening bipolar disorder. Treatment emergent psychotic or manic symptoms can occur in children or adolescents such as hallucinations, delusional thinking, or mania. Aggressive behavior or hostility is also often observed in children and adolescents taking medications for ADHD and should be monitored for the appearance of, or worsening of aggressive behavior or hostility.

Stimulants have been associated with long-term suppression of growth in pediatric patients. Growth should be monitored during treatment with Evekeo, and patients not growing or gaining height or weight as expected may need to have their treatment interrupted.

**Adverse Reactions**

The most common side effects reported with Evekeo treatment include palpitations, tachycardia, hypertension, overstimulation, restlessness, dizziness, insomnia, euphoria, dyskinesia, dysphoria, tremor, headache, exacerbation of phonic tics and Tourette’s syndrome, seizures (mainly in patients with a history of seizures), visual disturbances, dry mouth, unpleasant taste, gastrointestinal disturbances, weight loss, urticaria, impotence, changes in libido, frequent or prolonged erections, and peripheral vasculopathy including Raynaud’s phenomenon.

For additional safety information, consult the Evekeo full Prescribing Information and Medication Guide in the pocket.

**References:**

2. Evekeo [package insert]. Atlanta, GA: Arbor Pharmaceuticals, LLC.

Evekeo is a registered trademark of Arbor Pharmaceuticals, LLC ©2015 Arbor Pharmaceuticals, LLC. All rights reserved. PP-EVE-US-0163 Printed in USA. September 2015.
About 50% of young patients who begin ADHD treatment discontinue it within a year¹
Re-evaluation of therapy may be critical to help optimize treatment and improve adherence

Max*—a 12-year-old starting a new middle school

HISTORY:
• Max was diagnosed with ADHD 2 years ago and is currently on a generic stimulant therapy
• Parents think current medication is working OK, but think Max seems agitated lately
• Max says he feels overwhelmed and struggles with prioritizing all the things he needs to do; he’s worried about fitting in and being able to keep up in a larger class and a new environment

*Patient portrayal.

EVEKEO® can be an integral part of a total treatment program for patients with ADHD

The only single-salt, immediate-release 1:1 racemic mixture of dextroamphetamine and levoamphetamine²

INDICATION
Evekeo® (amphetamine sulfate tablets, USP) is a prescription medicine for the treatment of narcolepsy, attention deficit disorder with hyperactivity as an integral part of a total treatment program and exogenous obesity as a short term adjunct in a regimen of weight reduction.

IMPORTANT SAFETY INFORMATION
Evekeo (amphetamine sulfate tablets, USP) is a federally controlled substance (CII) with a high risk of abuse or dependence. Prolonged use may lead to drug dependence and must be avoided. Subjects may obtain Evekeo for illegal non-therapeutic use or distribution to others, and therefore it should be prescribed or dispensed sparingly. Misuse of Evekeo may cause sudden death and serious cardiovascular adverse events.

Please see full Important Safety Information on reverse and full Prescribing Information and Medication Guide, including Boxed Warning regarding abuse and dependence, in the pocket.
EVEKEO® demonstrated $P<0.0001$ significance in improvement of performance in number of problems attempted and number of problems correct vs placebo$^3$

**Indication**

Evekeo® (amphetamine sulfate tablets, USP) is a prescription medicine for the treatment of narcolepsy, attention deficit disorder with hyperactivity as an integral part of a total treatment program and exogenous obesity as a short-term adjunct in a regimen of weight reduction.

**Important Safety Information**

**Contraindications**

Evekeo is contraindicated in patients:
- with a history of advanced arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension, hyperthyroidism, known hypersensitivity or idiosyncrasy to the sympathomimetic amines
- that are tense or agitated
- with a history of drug abuse
- taking or who have taken monoamine oxidase inhibitor (MAOI) within 14 days. Hypertensive crises may result.

**Warnings and Precautions**

Sudden death has been reported in children and adolescents with structural cardiac abnormalities or other serious heart problems in association with CNS stimulant treatment at usual doses. Sudden death, stroke and myocardial infarction have been reported in adults taking stimulant drugs at usual doses for ADHD. Stimulant medications can cause an increase in blood pressure (mean increase about 2-4 mmHg) and heart rate (mean increase about 3-6 bpm). All patients should be monitored for larger changes in heart rate and blood pressure.

Children, adolescents, or adults who are being considered for treatment with Evekeo should have a careful history (including assessment for a family history of sudden death or ventricular arrhythmia) and physical exam to assess for the presence of cardiac disease. **Patients developing any signs of heart problems such as exertional chest pain, unexplained syncope, or other symptoms suggestive of cardiac disease while taking Evekeo should undergo a prompt cardiac evaluation.**

Stimulants may exacerbate symptoms in patients with pre-existing psychotic disorder or in patients with new or worsening bipolar disorder. Treatment emergent psychotic or manic symptoms can occur in children or adolescents such as hallucinations, delusional thinking, or mania. Aggressive behavior or hostility is also often observed in children and adolescents taking medications for ADHD and should be monitored for the appearance of, or worsening of aggressive behavior or hostility.

**Adverse Reactions**

The most common side effects reported with Evekeo treatment include palpitations, tachycardia, hypertension, overstimulation, restlessness, dizziness, insomnia, euphoria, dyskinesia, dysphoria, tremor, headache, exacerbation of phonic tics and Tourette’s syndrome, seizures (mainly in patients with a history of seizures), visual disturbances, dry mouth, unpleasant taste, gastrointestinal disturbances, weight loss, urticaria, impotence, changes in libido, frequent or prolonged erections, and peripheral vasculopathy including Raynaud’s phenomenon.

**For additional safety information, consult the Evekeo full Prescribing Information and Medication Guide in the pocket.**

**References:**
ADHD affects 9.5% of all children aged 6 to 17 years in the United States\(^1\) Early intervention may be critical to long-term success

**Jacob*—a 6-year-old starting full-day kindergarten**

**HISTORY:**
- Mother describes Jacob as “full of energy”
- Preschool teacher has voiced concern about Jake having difficulty sitting still and being severely distracted in class
- Jake admits to losing things a lot and not being able to pay attention to teachers or his parents
- ADHD recently confirmed by psychological assessment with stimulant therapy recommended as part of a total treatment program

*Patient portrayal.

**EVEKEO\(^\circledast\) can be an integral part of a total treatment program for patients with ADHD**

The only single-salt, immediate-release 1:1 racemic mixture of dextroamphetamine and levoamphetamine\(^2\)

**INDICATION**

Evekeo\(^\circledast\) (amphetamine sulfate tablets, USP) is a prescription medicine for the treatment of narcolepsy, attention deficit disorder with hyperactivity as an integral part of a total treatment program and exogenous obesity as a short term adjunct in a regimen of weight reduction.

**IMPORTANT SAFETY INFORMATION**

Evekeo (amphetamine sulfate tablets, USP) is a federally controlled substance (CII) with a high risk of abuse or dependence. Prolonged use may lead to drug dependence and must be avoided. Subjects may obtain Evekeo for illegal non-therapeutic use or distribution to others, and therefore it should be prescribed or dispensed sparingly.

Misuse of Evekeo may cause sudden death and serious cardiovascular adverse events.

Please see full Important Safety Information on reverse and full Prescribing Information and Medication Guide, including Boxed Warning regarding abuse and dependence, in the pocket.
EVEKEO® demonstrated highly significant improvement of SKAMP-Combined scores compared with placebo³

**EVEKEO: SKAMP-Combined**

![Graph showing improvement over time](image)

- A single morning dose of EVEKEO at 8 am demonstrated significant efficacy (P<0.0001) vs placebo at all measured time points from 45 minutes through 10 hours post-dose.

**Study details:** SKAMP-Combined measurement includes attention, deportment, quality of work, and compliance subscales, and is a standardized, validated classroom assessment tool consisting of 13 items used for evaluating inattention and behavioral symptoms of ADHD.

**Least squares mean:** Mean calculated using a statistical model.

**Indication**

Evekeo® (amphetamine sulfate tablets, USP) is a prescription medicine for the treatment of narcolepsy, attention deficit disorder with hyperactivity as an integral part of a total treatment program and exogenous obesity as a short-term adjunct in a regimen of weight reduction.

**Important Safety Information**

Evekeo (amphetamine sulfate tablets, USP) is a federally controlled substance (CII) with a high risk of abuse or dependence. Prolonged use may lead to drug dependence and must be avoided. Subjects may obtain Evekeo for illegal non-therapeutic use or distribution to others, and therefore it should be prescribed or dispensed sparingly. Misuse of Evekeo may cause sudden death and serious cardiovascular adverse events.

**Contraindications**

Evekeo is contraindicated in patients:

- with a history of advanced arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension, hyperthyroidism, known hypersensitivity or idiosyncrasy to the sympathomimetic amines
- that are tense or agitated
- with a history of drug abuse
- taking or who have taken monoamine oxidase inhibitor (MAOI) within 14 days. Hypertensive crises may result.

**Warnings and Precautions**

Sudden death has been reported in children and adolescents with structural cardiac abnormalities or other serious heart problems in association with CNS stimulant treatment at usual doses. Sudden death, stroke and myocardial infarction have been reported in adults taking stimulant drugs at usual doses for ADHD. Stimulant medications can cause an increase in blood pressure (mean increase about 2-4 mmHg) and heart rate (mean increase about 3-6 bpm). All patients should be monitored for larger changes in heart rate and blood pressure.

Children, adolescents, or adults who are being considered for treatment with Evekeo should have a careful history (including assessment for a family history of sudden death or ventricular arrhythmia) and physical exam to assess for the presence of cardiac disease. Patients developing any signs of heart problems such as exertional chest pain, unexplained syncope, or other symptoms suggestive of cardiac disease while taking Evekeo should undergo a prompt cardiac evaluation.

Stimulants may exacerbate symptoms in patients with pre-existing psychotic disorder or in patients with new or worsening bipolar disorder. Treatment emergent psychotic or manic symptoms can occur in children or adolescents such as hallucinations, delusional thinking, or mania. Aggressive behavior or hostility is also often observed in children and adolescents taking medications for ADHD and should be monitored for the appearance of, or worsening of aggressive behavior or hostility.

Stimulants have been associated with long-term suppression of growth in pediatric patients. Growth should be monitored during treatment with Evekeo, and patients not growing or gaining height or weight as expected may need to have their treatment interrupted.

**Adverse Reactions**

The most common side effects reported with Evekeo treatment include palpitations, tachycardia, hypertension, overstimulation, restlessness, dizziness, insomnia, euphoria, dyskinesia, dysphoria, tremor, headache, palpitations, tachycardia, hypertension, overstimulation, exacerbation of phonic tics and Tourette’s syndrome, seizures (mainly in patients with a history of seizures), visual disturbances, dry mouth, unpleasant taste, gastrointestinal disturbances, weight loss, urticaria, impotence, changes in libido, frequent or prolonged erections, and peripheral vasculopathy including Raynaud’s phenomenon.

For additional safety information, consult the Evekeo full Prescribing Information and Medication Guide in the pocket.

**References:**


**Evekeo is a registered trademark of Arbor Pharmaceuticals, LLC. ©2015 Arbor Pharmaceuticals, LLC. All rights reserved.**